The presence of the BCR-ABL1 abnormality confirms the clinical diagnosis of CML, a type of ALL, and rarely acute myeloid leukemia (AML). This test looks at chromosomes under a microscope to detect structural and/or numerical abnormalities.
Chronic myeloid leukemia, BCR/ABL-positive. The 2018/2019 edition of ICD-10-CM C92.1 became effective on October 1, 2018. This is the American ICD-10-CM version of C92.1 - other international versions of ICD-10 C92.1 may differ.
The presence of the gene sequence known as BCR-ABL1 confirms the diagnosis of CML and a form of acute lymphoblastic lymphoma (ALL), specifically a type of B-lymphoblastic leukemia/lymphoma. In very rare cases, the abnormal chromosome is linked to cases of acute myeloid leukemia and T-lymphoblastic leukemia/lymphoma.
Of those who have CML, 90-95% have the Ph chromosome if tested by cytogenetics and 100% have the BCR-ABL1 gene sequence by FISH and/or qualitative BCR-ABL1 molecular testing. About 30% of adults with B-ALL and 2-4% of children with B-ALL are positive for the Ph chromosome and/or the BCR-ABL1 gene sequence.
A BCR-ABL genetic test looks for a genetic mutation (change) on a specific chromosome. Chromosomes are the parts of your cells that contain your genes. Genes are parts of DNA passed down from your mother and father. They carry information that determines your unique traits, such as height and eye color.
CPT® 81206, Under Genetic Analysis Procedures The Current Procedural Terminology (CPT®) code 81206 as maintained by American Medical Association, is a medical procedural code under the range - Genetic Analysis Procedures.
Chronic myeloid leukemia (CML) cells contain an abnormal gene, BCR-ABL, that isn't found in normal cells. This gene makes a protein, BCR-ABL, which causes CML cells to grow and reproduce out of control. BCR-ABL is a type of protein known as a tyrosine kinase.
The presence of the gene sequence known as BCR-ABL1 confirms the diagnosis of CML and a form of acute lymphoblastic lymphoma (ALL), specifically a type of B-lymphoblastic leukemia/lymphoma. In very rare cases, the abnormal chromosome is linked to cases of acute myeloid leukemia and T-lymphoblastic leukemia/lymphoma.
TestCPT Code1.BCR-ABL t(9;22) Quantitative GenoTRACE Assay814792.BCR/ABL, Quantitative, t(9;22) for CML, ALL814793.Qualitative w/ reflex to BCR-ABL1814794.BCR-ABL, t(9;22) Translocation Qualitative by RT-PCR8147914 more rows•Jul 26, 2013
Providers should refer to the current CPT book for applicable CPT codes.CodeDescription81205Bckdhb gene81206Bcr/abl1 gene major bp81207Bcr/abl1 gene minor bp81208Bcr/abl1 gene other bp72 more rows•Dec 30, 2021
Philadelphia chromosome. A piece of chromosome 9 and a piece of chromosome 22 break off and trade places. The BCR-ABL gene is formed on chromosome 22 where the piece of chromosome 9 attaches. The changed chromosome 22 is called the Philadelphia chromosome.
Normal ABL1 is a tumor suppressor in BCR-ABL1–induced leukemia.
The ABL1 gene provides instructions for making a protein involved in many processes in cells throughout the body. The ABL1 protein functions as a kinase, which is an enzyme that changes the activity of other proteins by adding a cluster of oxygen and phosphorus atoms (a phosphate group) at specific positions.
The product of this fusion BCR-ABL gene is a constitutively active protein tyrosine kinase, p210 BCR-ABL, that promotes cellular proliferation and suppresses apoptosis. BCR-ABL kinase activity is critical to the development of CML (5).
Atypical chronic myeloid leukemia (aCML), BCR-ABL1 negative is a rare myelodysplastic syndrome/myeloproliferative neoplasm for which no current standard of care exists. The blood smear of patients with aCML showed prominent immature granulocytosis, and granulocytic dysplasia.
CPT codes, descriptions and other data only are copyright 2020 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.
Title XVIII of the Social Security Act, §1833 (e), prohibits Medicare payment for any claim lacking the necessary documentation to process the claim.
The following coding and billing guidance is to be used with its associated Local Coverage Determination.
Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the article does not apply to that Bill Type.
Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the article, services reported under other Revenue Codes are equally subject to this coverage determination.
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Do not reject specimens, send to laboratory for screening. Collect 5 mL whole blood or 3 mL bone marrow in an EDTA (lavender-top) tube. Whole blood or bone marrow is shipped at room temperature or refrigerated (cold packs). Do not freeze whole blood or bone marrow.
Do not reject specimens, send to laboratory for screening. Collect 5 mL whole blood or 3 mL bone marrow in an EDTA (lavender-top) tube. Whole blood or bone marrow is shipped at room temperature or refrigerated (cold packs). Do not freeze whole blood or bone marrow.
The protein coded for by the abnormal BCR-ABL1 fusion gene is a type of enzyme called a tyrosine kinase. That enzyme is responsible for the uncontrolled growth of leukemic cells.
The BCR-ABL1 gene sequence is one such acquired change that is formed when pieces of chromosome 9 and chromosome 22 break off and switch places. When this occurs, the ABL1 region in chromosome 9 fuses with the BCR gene region in chromosome 22.
It may take one to several days for your results to be available.
BCR-ABL1 refers to a gene sequence found in an abnormal chromosome 22 of some people with certain forms of leukemia. Unlike most cancers, the cause of chronic myelogenous leukemia (CML) and some other leukemias can be traced to a single, specific genetic abnormality in one chromosome. The presence of the gene sequence known as BCR-ABL1 confirms ...
The resulting chromosome 22 that has the BCR-ABL1 gene sequence is known as the Philadelphia (Ph) chromosome because that is where it was first discovered.
Therefore, for a given patient, the quantitative BCR-ABL1 molecular testing should be performed by the same laboratory or referred to a laboratory that follows universal reporting criteria. Rising and falling levels of BCR-ABL1 are usually more important than a single test result.
Since the treatment for BCR-ABL1 -related leukemias specifically targets the tyrosine kinase protein produced, these people can still be monitored with quantitative BCR-ABL1 molecular testing. Very rarely, neither the Ph chromosome nor the BCR-ABL1 mutation can be found in people who seem to have CML.
CPT codes, descriptions and other data only are copyright 2021 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.
Breakpoint testing for BCR-ABL1 is commonly performed as a combination or panel of tests (major, minor and other breakpoints). To report multiple tests assigned a single ID, submit CPT ® code 81479. This guideline includes the following CPT ® code combinations:
Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the article does not apply to that Bill Type.
Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the article, services reported under other Revenue Codes are equally subject to this coverage determination.